MARKET OVERVIEW
The Cancer Pain Management Solutions Market is anticipated to gain a telling impetus while riding on the moderate to severe pattern of pain experienced by patients worldwide. Nearly 70% of cancer patients could suffer from chronic pain because of spinal cord injuries, 28% due to multiple sclerosis, and 8% on account of stroke on a global platform. Besides this, above 75% of the patients are expected to complain of a gradual surge in pain with the progression of the disease. Therefore, an increase in the count of patients experiencing such pain could positively affect the growth of the market. Furthermore, with elevating research and development focus, there could be a range of drugs in the pipeline. This is envisaged to bode well for the global cancer pain management market as more drugs could increase demand.
MARKET SCOPE
The "Global Cancer Pain Management Solutions Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the cancer pain management solutions market with detailed market segmentation by pain management type, treatment type, disease indication, end use and geography. The report provides key statistics on the market status of the leading cancer pain management solutions market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on pain management type, the global cancer pain management solutions market is segmented into acute pain management, moderate pain management, and severe pain management.
- On the basis of treatment type, the market is segmented into medications, and devices or systems. Medications are again segmented into opioids/narcotics, non-opioids, and nerve blocks, and devices is segmented into electrical stimulation devices, analgesic infusion pumps, neurostimulation devices, and radiofrequency ablation devices.
- On the basis of disease indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others.
- On the basis of end use, the market is segmented into hospitals, clinics, and others.
MARKET DYNAMICS
Drivers
- Rise in the incidences of cancer globally.
- Growing awareness regarding cancer and its pain management.
- Increased healthcare expenditures, increase in government initiatives to alleviate cancer
- Surge in geriatric population
Restraints
- The adverse effect associated with the use of cancer pain drugs are the major restraining factor for this market.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The cancer pain management solutions market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the cancer pain management solutions market in these regions.
IMPACT OF COVID-19 ON CANCER PAIN MANAGEMENT SOLUTIONS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the cancer pain management solutions market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from cancer pain management solutions market are anticipated to lucrative growth opportunities in the future with the rising demand for cancer pain management solutions in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the cancer pain management solutions market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly.
- Pfizer
- Johnson & Johnson
- Purdue Pharma
- Endo Pharmaceuticals Plc.
- Forest Laboratories Inc.
- GlaxoSmithKline Plc.
- F. Hoffmann-La Roche Ltd.
- Baxter International Inc.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Cancer Pain Management Solutions Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ XX Million |
Market Size by 2031 | US$ XX Million |
Global CAGR (2023 - 2031) | XX% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Pain Management Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
- Broth Market
- Electronic Shelf Label Market
- Bathroom Vanities Market
- Machine Condition Monitoring Market
- Pressure Vessel Composite Materials Market
- Greens Powder Market
- Neurovascular Devices Market
- Diaper Packaging Machine Market
- Quantitative Structure-Activity Relationship (QSAR) Market
- Artificial Intelligence in Defense Market
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies
1. Teva Pharmaceutical Industries Ltd.
2. Eli Lilly.
3. Pfizer
4. Johnson & Johnson
5. Purdue Pharma
6. Endo Pharmaceuticals Plc.
7. Forest Laboratories Inc.
8. GlaxoSmithKline Plc.
9. F. Hoffmann-La Roche Ltd.
10. Baxter International Inc.
11. Valeant Pharmaceuticals International Inc.
12. Daiichi Sankyo Co., Ltd
13. Grnenthal Pharma GmbH & Co. KG
14. Hisamitsu Pharmaceutical Co., Inc
15. Insys Therapeutics, Inc
16. Mundipharma International Limited
17. Orexo AB
18. Aoxing Pharmaceutical Company, Inc
19. BioDelivery Sciences International, Inc.
1. Teva Pharmaceutical Industries Ltd.
2. Eli Lilly.
3. Pfizer
4. Johnson & Johnson
5. Purdue Pharma
6. Endo Pharmaceuticals Plc.
7. Forest Laboratories Inc.
8. GlaxoSmithKline Plc.
9. F. Hoffmann-La Roche Ltd.
10. Baxter International Inc.
11. Valeant Pharmaceuticals International Inc.
12. Daiichi Sankyo Co., Ltd
13. Grnenthal Pharma GmbH & Co. KG
14. Hisamitsu Pharmaceutical Co., Inc
15. Insys Therapeutics, Inc
16. Mundipharma International Limited
17. Orexo AB
18. Aoxing Pharmaceutical Company, Inc
19. BioDelivery Sciences International, Inc.